Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lipigon Pharmaceuticals

Less than 1K followers
Overview
Investor views
All
Press releases
ShowingAll content types

Regulatory press release03.12.2025, 18.55

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals
Press release21.11.2025, 12.19

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals
Press release14.10.2025, 22.58

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release26.08.2025, 14.28

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals
Regulatory press release06.07.2025, 09.03

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals
Press release27.05.2025, 08.36

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals
Press release31.03.2025, 08.25

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals
Regulatory press release20.03.2025, 12.15

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals
Press release21.11.2024, 14.12

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals
Regulatory press release21.11.2024, 10.00

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals
Press release18.09.2024, 12.51

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals
Press release28.08.2024, 07.43

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals
Regulatory press release09.07.2024, 14.00

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals
Press release20.06.2024, 08.30

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals
Press release29.05.2024, 08.03

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals
Press release15.05.2024, 08.28

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals
Regulatory press release14.05.2024, 07.53

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals
Press release23.02.2024, 08.08

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals
Press release07.02.2024, 16.00

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals
Press release12.12.2023, 10.11

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals